Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Actas Dermosifiliogr ; 115(4): 356-367, 2024 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-37714301

ABSTRACT

Hyperhidrosis, or excessive sweating, is characterized by overactivity of the eccrine sweat glands, usually associated with dysfunction of the autonomic nervous system. Primary focal hyperhidrosis is the most common form and can affect the axillae, palms, soles, and/or face, often leading to significantly impaired quality of life and social functioning. Treatment is complex. Topical antiperspirants are normally recommended as the first-line treatment for mild hyperhidrosis. Multiple clinical trials and prospective studies support the efficacy and tolerability of oral and topical anticholinergics in the management of hyperhidrosis. Topical glycopyrronium, which has been investigated in at least 8 clinical trials enrolling more than 2000 patients, is probably the first-line pharmacological treatment for axillary hyperhidrosis in patients with moderate to severe disease poorly controlled with topical antiperspirants. Second-line treatments include botulinum toxin injections, microwave treatment, and oral anticholinergics. We review the use of topical anticholinergics in the management of focal hyperhidrosis in adults and children.


Subject(s)
Botulinum Toxins, Type A , Hyperhidrosis , Adult , Child , Humans , Antiperspirants/therapeutic use , Cholinergic Antagonists/therapeutic use , Quality of Life , Prospective Studies , Sympathectomy , Hyperhidrosis/drug therapy
2.
J AAPOS ; 26(1): 42-43, 2022 02.
Article in English | MEDLINE | ID: mdl-34798293

ABSTRACT

Acute-onset anisocoria or mydriasis in children carries a broad differential diagnosis and includes both benign and life-threatening causes, ranging from systemic or topical drug use to peripheral or central nervous system disease. The topical anticholinergic agent glycopyrronium (approved by the Food and Drug Administration in June 2018) is used to treat hyperhidrosis. We present the first case series of pediatric patients presenting with acute mydriasis due to exposure to glycopyrronium wipes. Six cases (ages 12-16) were identified: 3 presented emergently and 3 to a primary care physician. Additional symptoms included blurry vision (4/6) and unilateral headache (1/6). In 3 cases, use of glycopyrronium wipes was not elicited initially, neuroimaging was obtained, and ophthalmology (2/3) or neurology (1/3) was consulted. One patient remained undiagnosed and presented emergently again 2 months later. In all patients, symptoms resolved without further treatment.


Subject(s)
Hyperhidrosis , Mydriasis , Adolescent , Anisocoria/chemically induced , Anisocoria/diagnosis , Antiperspirants/therapeutic use , Child , Glycopyrrolate , Humans , Hyperhidrosis/chemically induced , Hyperhidrosis/drug therapy , Mydriasis/chemically induced , Mydriasis/diagnosis
4.
J Am Acad Dermatol ; 81(3): 669-680, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30710603

ABSTRACT

Hyperhidrosis (HH) is a chronic disorder of excess sweat production that may have a significant adverse effect on quality of life. A variety of treatment modalities currently exist to manage HH. Initial treatment includes lifestyle and behavioral recommendations. Antiperspirants are regarded as the first-line therapy for primary focal HH and can provide significant benefit. Iontophoresis is the primary remedy for palmar and plantar HH. Botulinum toxin injections are administered at the dermal-subcutaneous junction and serve as a safe and effective treatment option for focal HH. Oral systemic agents are reserved for treatment-resistant cases or for generalized HH. Energy-delivering devices such as lasers, ultrasound technology, microwave thermolysis, and fractional microneedle radiofrequency may also be utilized to reduce focal sweating. Surgery may be considered when more conservative treatments have failed. Local surgical techniques, particularly for axillary HH, include excision, curettage, liposuction, or a combination of these techniques. Sympathectomy is the treatment of last resort when conservative treatments are unsuccessful or intolerable, and after accepting secondary compensatory HH as a potential complication. A review of treatment modalities for HH and a sequenced approach are presented.


Subject(s)
Hyperhidrosis/therapy , Quality of Life , Sweat Glands/surgery , Administration, Cutaneous , Antiperspirants/therapeutic use , Botulinum Toxins, Type A/administration & dosage , Cholinergic Antagonists/administration & dosage , Cognitive Behavioral Therapy , Combined Modality Therapy/methods , Curettage , Humans , Hyperhidrosis/etiology , Hyperhidrosis/psychology , Injections, Subcutaneous , Iontophoresis , Microwaves/therapeutic use , Radiofrequency Ablation , Sweat Glands/physiopathology , Sweat Glands/radiation effects , Sweating/physiology , Sweating/radiation effects , Sympathectomy , Treatment Outcome , Ultrasonic Therapy
6.
Chest ; 154(5): 1115-1120, 2018 11.
Article in English | MEDLINE | ID: mdl-30243566

ABSTRACT

BACKGROUND: Malignant pleural effusion (MPE) is common and imposes a significant burden on patients and health-care providers. Most patients require definitive treatment, usually drainage and chemical pleurodesis, to relieve symptoms and prevent fluid recurrence. Thoracic ultrasound (TUS) can identify the presence of pleural adhesions in other clinical scenarios, and could therefore have a role in predicting long-term pleurodesis success or failure in MPE. METHODS: Patients undergoing chest tube drainage and talc slurry pleurodesis for symptomatic MPE were recruited to a prospective observational cohort pilot study assessing whether TUS findings pre-talc and post-talc instillation predicted treatment outcome. Participants underwent TUS examination immediately before, and 24 h after talc slurry administration to derive pleural adherence scores for the affected hemithorax. The recorded TUS scans were additionally scored by two independent assessors blinded to the patient's clinical status. The primary outcome was pleurodesis success at 1-month and 3-month follow-up. RESULTS: Eighteen participants were recruited to the pilot study. Participants who suffered pleurodesis failure had a lower pleural adherence score at 24 h post-talc instillation than those who were successful (difference of 6.27; 95% CI, 3.94-8.59). TUS examination was acceptable to patients, while TUS scoring was highly consistent across all assessors (intraclass correlation coefficient, 0.762; 95% CI, 0.605-0.872). CONCLUSION: A TUS-derived pleural adherence score may facilitate early prediction of long-term outcomes following chemical pleurodesis, with implications for personalized care and decision making in MPE. Further research is needed to evaluate this novel finding. TRIAL REGISTRY: ClinicalTrials.gov; No. NCT02625675; URL: www.clinicaltrials.gov.


Subject(s)
Drainage , Pleural Cavity , Pleural Effusion, Malignant , Pleurodesis , Talc/therapeutic use , Ultrasonography/methods , Aged , Antiperspirants/therapeutic use , Drainage/adverse effects , Drainage/methods , Female , Humans , Male , Middle Aged , Pilot Projects , Pleural Cavity/diagnostic imaging , Pleural Cavity/pathology , Pleural Effusion, Malignant/diagnosis , Pleural Effusion, Malignant/therapy , Pleurodesis/adverse effects , Pleurodesis/methods , Predictive Value of Tests , Prognosis , Prospective Studies , Secondary Prevention , Tissue Adhesions/complications , Tissue Adhesions/diagnostic imaging
7.
J Drugs Dermatol ; 17(7): 745-748, 2018 Jul 01.
Article in English | MEDLINE | ID: mdl-30005096

ABSTRACT

Primary axillary hyperhidrosis (PAH), or excessive sweating limited to the axillary area, is a debilitating disease that severely and negatively impacts social and psychological well-being. Several treatment options are available for PAH; however, these options have been shown to provide varying effectiveness. Recent studies have suggested another treatment alternative offering an effective PAH treatment option with reported long-term results. High intensity focused fractional radiofrequency (HIFRF) microneedling is FDA cleared for the treatment of facial wrinkles. The system is designed with a unique technology that is safe for use on patients presenting with all skin types. Based on its unique design and the clinical trial experience reported in the literature by Kim, et al1 and others,2,5 we offer it to our patients as a beneficial treatment option for primary axillary hyperhidrosis (PAH). We present here a clinical experience summary from three US centers providing hyperhidrosis treatments using the high-intensity radio-frequency device, including treatment parameters, clinical outcomes, and pre- and post-treatment images. J Drugs Dermatol. 2018;17(7):745-748.


Subject(s)
Antiperspirants/therapeutic use , Hyperhidrosis/therapy , Radiofrequency Therapy , Adult , Aged , Axilla , Clinical Trials as Topic , Female , Humans , Hyperhidrosis/diagnosis , Male , Middle Aged , Needles/adverse effects , Patient Satisfaction , Radio Waves/adverse effects , Treatment Outcome , Young Adult
8.
Epidemiology ; 29(1): 41-49, 2018 01.
Article in English | MEDLINE | ID: mdl-28863045

ABSTRACT

BACKGROUND: It has been posited that there is an association between perineal talc use and the incidence of ovarian cancer. To date, this has only been explored in observational studies. OBJECTIVES: To perform a meta-analysis to evaluate the association between perineal talc use and risk of ovarian cancer. METHODS: Studies were identified using six electronic databases. Observational studies involving at least 50 cases of ovarian cancer were eligible for inclusion. We analyzed the association between ovarian cancer, including specific types, and any perineal talc use, long-term (>10 years) use, total lifetime applications, and use on diaphragms or sanitary napkins. A subgroup analysis was performed, stratifying by study design and population. RESULTS: We identified 24 case-control (13,421 cases) and three cohort studies (890 cases, 181,860 person-years). Any perineal talc use was associated with increased risk of ovarian cancer (OR = 1.31; 95% CI = 1.24, 1.39). More than 3600 lifetime applications (OR = 1.42; 95% CI = 1.25, 1.61) were slightly more associated with ovarian cancer than <3600 (OR = 1.32; 95% CI = 1.15, 1.50). An association with ever use of talc was found in case-control studies (OR = 1.35; 95% CI = 1.27, 1.43), but not cohort studies (OR = 1.06; 95% CI = 0.90, 1.25). However, cohort studies found an association between talc use and invasive serous type ovarian cancer (OR = 1.25; 95% CI = 1.01, 1.55). We found an increased risk of serous and endometrioid, but not mucinous or clear cell subtypes. CONCLUSIONS: In general, there is a consistent association between perineal talc use and ovarian cancer. Some variation in the magnitude of the effect was found when considering study design and ovarian cancer subtype.


Subject(s)
Antiperspirants/therapeutic use , Carcinoma, Endometrioid/epidemiology , Neoplasms, Cystic, Mucinous, and Serous/epidemiology , Ovarian Neoplasms/epidemiology , Perineum , Talc/therapeutic use , Case-Control Studies , Female , Humans , Incidence , Odds Ratio , Risk Factors
9.
Wilderness Environ Med ; 28(2): 139-149, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28602272

ABSTRACT

The purpose of this systematic review was to determine if sock, antiperspirant, or barrier strategies were effective in prevention of friction blisters in wilderness and outdoor pursuits. A search of PubMed and EMBASE was conducted. Title, abstract, and full text articles were screened by 2 authors using predetermined inclusion and exclusion criteria to identify prospective controlled trials investigating prevention methods for friction blisters involving the foot. Only blisters associated with wilderness and outdoor pursuits (running, hiking, marching, etc.) were considered. Extraction of a predetermined data set was accomplished using a piloted form. Confidence in effect estimates were determined utilizing the Scottish Intercollegiate Guidelines Network methodology checklist. Literature search resulted in 806 discrete articles. After screening, 11 studies were identified for inclusion in systematic review. Included studies investigated 5 sock, 3 antiperspirant, and 3 barrier strategies. Only 2 articles were determined to have moderate confidence in effect estimate. Clinical and methodologic diversity precluded meta-analysis. Despite the high frequency, discomfort, and associated cost there is a paucity of high-quality quality evidence in support of socks, antiperspirants, or barriers for the prevention of friction blisters. Moderate confidence in effect estimate suggests that paper tape may be an effective form of barrier prevention.


Subject(s)
Blister/prevention & control , Friction , Antiperspirants/therapeutic use , Clothing , Foot , Humans , Running , Surgical Tape/statistics & numerical data , Wilderness
10.
J Dermatolog Treat ; 28(7): 582-590, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28318360

ABSTRACT

Axillary hyperhidrosis is characterized by an increased amount of sweat production, localized to the armpits, to compensate for environmental conditions and to control thermoregulation. It affects about 3.12% of the US population. It has a significant effect on one's psychological and physical health, as well as one's occupational life. The objective of this paper is to review the epidemiology, clinical presentation, pathophysiology, histology, genetics, and management and treatment of axillary hyperhidrosis.


Subject(s)
Hyperhidrosis/diagnosis , Administration, Topical , Antiperspirants/therapeutic use , Botulinum Toxins/therapeutic use , Cholinergic Antagonists/therapeutic use , Chromosomes, Human, Pair 14 , Humans , Hyperhidrosis/drug therapy , Hyperhidrosis/genetics , Sweat Glands/metabolism , Sweat Glands/pathology , Sweating , Sympathectomy
11.
Cutis ; 97(6): 401-3, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27416083

ABSTRACT

Residual limb dermatologic problems are a common concern among young active traumatic amputee patients who strive to maintain an active lifestyle. Hyperhidrosis of residual limbs is a recognized inciting factor that often contributes to residual limb dermatoses and is driven by the design of the prosthetic liner covering the residual limb. Treatment of hyperhidrosis in this population presents a unique challenge. Several accepted treatments of hyperhidrosis can offer some relief but have been limited by lack of results or side-effect profiles. Microwave thermal ablation has presented an enticing potential for residual limb hyperhidrosis.


Subject(s)
Ablation Techniques/methods , Amputation Stumps , Amputation, Traumatic , Antiperspirants/therapeutic use , Botulinum Toxins/therapeutic use , Hyperhidrosis/therapy , Neurotoxins/therapeutic use , Veterans , Artificial Limbs , Hair Removal , Humans , Iontophoresis , Microwaves
13.
Ann Dermatol Venereol ; 142(4): 252-61, 2015 Apr.
Article in French | MEDLINE | ID: mdl-25697587

ABSTRACT

Hyperhidrosis continues to be undertreated in our view, despite its propensity to considerably impair quality of life. We shall break down therapeutic approaches to hyperhidrosis into several steps: (a) determine the physiological causes of excess sweating; (b) establish the type of hyperhidrosis involved and screen for causes of secondary hyperhidrosis before diagnosing essential hyperhidrosis; (c) evaluate the severity of the hyperhidrosis by means of a validated scale (HDSS score), Minor's starch-iodine test or gravimetric analysis; (d) select one of the medical therapies currently available, i.e. topical therapy (antiperspirants, iontophoresis or botulinum toxin injection), systemic therapy (oxybutynin) or surgery (thoracic sympathectomy).


Subject(s)
Hyperhidrosis/therapy , Algorithms , Antiperspirants/therapeutic use , Botulinum Toxins, Type A/therapeutic use , Cholinergic Antagonists/therapeutic use , Decision Trees , Disease Management , Humans , Hyperhidrosis/diagnosis , Hyperhidrosis/physiopathology , Iontophoresis , Severity of Illness Index , Staining and Labeling , Sweat Glands/physiopathology , Sympathectomy
14.
J Spec Oper Med ; 14(2): 95-97, 2014.
Article in English | MEDLINE | ID: mdl-24952049

ABSTRACT

Foot blisters are the most common medical problem faced by Soldiers during foot march operations and, if untreated, they can lead to infection. Foot blisters are caused by boots rubbing on the foot (frictional forces), which separates skin layers and allows fluid to seep in. Blisters can be prevented by wearing properly sized boots, conditioning feet through regular road marching, wearing socks that reduce reduce friction and moisture, and possibly applying antiperspirants to the feet.


Subject(s)
Antiperspirants/therapeutic use , Blister/prevention & control , Foot Injuries/prevention & control , Military Personnel , Protective Clothing , Shoes , Humans
15.
Breast ; 23(3): 244-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24656636

ABSTRACT

BACKGROUND: Elevated concentrations of doxorubicin are found in eccrine sweat glands of the palms and soles. We therefore evaluated an antiperspirant as preventive treatment for palmar-plantar erythrodysesthesia (hand-foot syndrome) in patients with metastatic breast cancer treated with pegylated liposomal doxorubicin. PATIENTS AND METHODS: An antiperspirant containing aluminum chlorohydrate or placebo cream was applied to the left or right hand and foot in a double-blinded manner (intra-patient randomization). The primary endpoint was the rate of grade 2 or 3 palmar-plantar erythrodysesthesia. A secondary endpoint was the patient-reported symptom burden (tingling, numbness, pain, or skin problems). Using McNemar's matched pairs design, 53 patients were needed to detect a 20% difference between the treatment and placebo sides with a significance level of 5% and power of 90%. RESULTS: Grade 2 or 3 PPE occurred in 30 (58%) of 52 evaluable patients; in six patients adverse effects occurred on the placebo side but not on the treatment side, whereas one patient developed palmar-plantar erythrodysesthesia on the treatment side only (P = 0.07). Four patients developed grade 2 or 3 palmar-plantar erythrodysesthesia on their foot on the placebo side but not on the treatment side (P = 0.05). In the cohort with grade 2 or 3 palmar-plantar erythrodysesthesia there was a trend towards fewer dermatologic symptomatologies with the active treatment (P = 0.05), and no difference for other adverse events. CONCLUSION: Using topical aluminum chlorohydrate as an antiperspirant appears to reduce the incidence of grade 2 or 3 palmar-plantar erythrodysesthesia following pegylated liposomal doxorubicin chemotherapy for metastatic breast cancer.


Subject(s)
Aluminum Hydroxide , Breast Neoplasms , Chlorides , Doxorubicin/analogs & derivatives , Hand-Foot Syndrome/prevention & control , Administration, Topical , Aged , Aluminum Hydroxide/pharmacology , Aluminum Hydroxide/therapeutic use , Antiperspirants/pharmacology , Antiperspirants/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Chlorides/pharmacology , Chlorides/therapeutic use , Double-Blind Method , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Drug Monitoring/methods , Female , Humans , Middle Aged , Neoplasm Staging , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Severity of Illness Index , Skin Cream , Treatment Outcome
16.
J Cosmet Laser Ther ; 15(5): 286-9, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23465053

ABSTRACT

Hyperhidrosis has recently been described as a novel adverse effect of laser-assisted hair removal in the axillary area. Inguinal Hyperhidrosis (IH) is a localized and, typically, a primary form of hyperhidrosis affecting the groin area in individuals before age 25. IH has been reported in the literature after traumas and as a dysfunction of the central sympathetic nervous system. To the best of our knowledge, IH has never been reported as secondary to laser-assisted hair removal. Herein, we report three cases of IH following depilatory laser of the inguinal zone. Three female patients with no relevant medical history presented with the complaint of excessive sweating in the inguinal area after undergoing full bikini depilatory laser sessions. Although never described before, depilatory laser seems to trigger the occurrence of hyperhidrosis in the inguinal zone.


Subject(s)
Hair Removal/adverse effects , Hyperhidrosis/etiology , Lasers, Semiconductor/adverse effects , Adult , Aluminum Compounds/therapeutic use , Antiperspirants/therapeutic use , Female , Groin , Humans , Hyperhidrosis/drug therapy , Soaps/therapeutic use
17.
Hautarzt ; 63(6): 452-5, 2012 Jun.
Article in German | MEDLINE | ID: mdl-22653180

ABSTRACT

In Europe often no clear distinction is made between deodorant and antiperspirant. Particularly in Germany, the labeling "deo" is used for both. Only antiperspirants are capable of influencing the activity of eccrine sweat glands. In the treatment of focal hyperhidrosis, the use of aluminum chloride solutions represents the first choice. The efficacy is well documented in a variety of studies. Subjective side effects include pruritus and - less often - irritant dermatitis, which can be treated symptomatically and usually does not require discontinuation of the treatment. Rare variants of focal hyperhidrosis like auriculotemporal syndrome, Ross syndrome and nevus sudoriferus also are suitable for treatment with topical aluminum chloride hexahydrate solutions.


Subject(s)
Antiperspirants/adverse effects , Antiperspirants/therapeutic use , Dermatitis, Contact/etiology , Dermatitis, Contact/prevention & control , Hyperhidrosis/drug therapy , Pruritus/chemically induced , Pruritus/prevention & control , Antiperspirants/classification , Germany , Humans
19.
J Dtsch Dermatol Ges ; 10(2): 115-9, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21848980

ABSTRACT

BACKGROUND: Primary focal hyperhidrosis plantaris can cause impairment in social, physical, leisure and occupational activities. Topical treatment with aluminium chloride is the first-line treatment. The aim of this trial was to evaluate efficacy and safety of two different concentrations of aluminium chloride hexa-hydrate (12.5%, 30%) for 6 weeks. PATIENTS AND METHODS: 20 volunteers with hyperhidrosis plantaris were included. Efficacy was evaluated using a clinical rating scale of the hyperhidrosis level and qualitative assessments including Minor's (iodine-starch) test and a standardized sniff test. Furthermore a patient questionnaire and measurements of skin surface pH were done to evaluate the subjective assessments and side effects. RESULTS: The hyperhidrosis level significantly decreased in both concentrations. There were no differences in tolerability regarding the skin surface pH and the patient questionnaires. In addition the hidrotic areas decreased after application of both products and the sniff test improved. CONCLUSION: Topical application of an antiperspirant containing aluminium chloride reduced sweat production in plantar hyperhidrosis significantly. As both 12.5% and 30% were efficacious and safe, we would recommend 12.5% for outpatient treatment.


Subject(s)
Aluminum Compounds/administration & dosage , Antiperspirants/therapeutic use , Chlorides/administration & dosage , Hyperhidrosis/diagnosis , Hyperhidrosis/therapy , Adult , Aluminum Chloride , Aluminum Compounds/adverse effects , Aluminum Compounds/chemistry , Antiperspirants/adverse effects , Antiperspirants/chemistry , Chlorides/adverse effects , Chlorides/chemistry , Dose-Response Relationship, Drug , Female , Humans , Male , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...